OSL Stock Overview
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide.
OncoSil Medical Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.009|
|52 Week High||AU$0.051|
|52 Week Low||AU$0.008|
|1 Month Change||0%|
|3 Month Change||-18.18%|
|1 Year Change||-80.85%|
|3 Year Change||-92.80%|
|5 Year Change||-95.38%|
|Change since IPO||-95.50%|
Recent News & Updates
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite RiskyMay 24
Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn SituationFeb 03
Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?Oct 20
OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth PlansMay 13
OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five YearsMar 21
We're Not Worried About OncoSil Medical's (ASX:OSL) Cash BurnJan 26
How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?Dec 04
|OSL||AU Life Sciences||AU Market|
Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned -30.5% over the past year.
Return vs Market: OSL underperformed the Australian Market which returned -3.4% over the past year.
|OSL Average Weekly Movement||19.7%|
|Life Sciences Industry Average Movement||10.1%|
|Market Average Movement||8.8%|
|10% most volatile stocks in AU Market||17.8%|
|10% least volatile stocks in AU Market||3.1%|
Stable Share Price: OSL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: OSL's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited Fundamentals Summary
|OSL fundamental statistics|
Is OSL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OSL income statement (TTM)|
|Cost of Revenue||AU$1.59m|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-0.0057|
|Net Profit Margin||-772.98%|
How did OSL perform over the long term?See historical performance and comparison